Phase 3 N=745 Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
Phase 2 N=204 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change of Corneal Fluorescein Staining of the Inferior Cornea Region. — -1.00; -0.78; -0.78 units on a scale (Likert)
Phase 3 N=455 Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Conjunctival Staining — -1.9; -1.8; -1.2 score on a scale
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
Phase 4 N=42 The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers
Dry Eye
Primary: Difference in Contact Lens-related Discomfort at 12 Weeks Compared to Baseline — 71; 11 score on a scale — p=<0.01
Phase 2 N=80 Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change From Baseline to Week 12 in Schirmer Test (ST) Score in Millimeters — 1.25; 3.81 Millimeters — p=0.027
Phase 3 N=757 A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease — 0; 0 Participants
Phase 2 N=102 A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
Phase 4 N=80 Effect of Intraoperative Dexamethasone on Post-op Dry Eye
Dry Eye Syndromes
Primary: Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively — 311.15; 316.3 mOsmol/L — p=<.01
Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Phase 2 N=56 An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
Dry Eye
Primary: Change From Baseline in Ocular Discomfort — 1.35; 2.07 score on a scale
Phase 2 N=43 OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye
Dry Eye
Primary: Total Corneal Fluorescein Staining — 4.09; 5.05 units on a scale
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
Phase 2 N=300 A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Syndrome
Primary: Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness. — -0.7; -0.5; -0.4 units on a scale
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
Phase 2 N=85 Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) — -2.4; -1.3 score on a scale
Phase 2 N=9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event
Phase 2 N=158 A Clinical Trial to Assess Subjects With Dry Eye Disease.
Dry Eye
Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.066; 0.183 units on a scale
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
Phase 2 N=129 Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Posterior Blepharitis · Meibomian Gland Dysfunction
Primary: Adverse Events — 1; 1; 2; 0 adverse events
Phase 2 N=63 A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
Dry Eye Syndromes
Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.33; 0.44 score on a scale
Phase 3 N=258 An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Adverse Events — 68; 81 Count of participants
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
Phase 4 N=31 Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale